Polymorphism of XRCC1, XRCC3, and XPD Genes and Risk of Chronic Myeloid Leukemia

Table 2

Patient features at diagnosis according to the XRCC1, XPD, and XRCC3 genotypes.

	Overall	XRCC1 Arg194Trp			XRCC1 Arg280His			XRCC1 Arg399Gln			XRCC3 Thr241Met			XPD Lys751Gln
		Arg/Arg	Variant*	𝑃	Arg/Arg	Variant*	𝑃	Arg/Arg	Variant*	𝑃	Thr/Thr	Variant*	𝑃	Lys/Lys	Variant*	𝑃
Gender
Female	69 (44.2)	51	17	0.849	42	27	0.076	33	36	0.630	30	39	0.624	26	43	0.302
Male	87 (55.2)	68	20		40	47		38	49		34	53		25	62
Age
<50 years	68 (43.6)	55	13	0.259	34	34	0.629	37	31	0.053	32	36	0.192	22	46	1.00
>50 years	88 (56.4)	64	24		48	40		34	54		32	56		29	59
Clinical phases
CP	134 (85.9)	106	28	0.056	72	62	0.498	66	59	0.104	59	75	0.065	40	94	0.084
AP/BP	22 (14.1)	13	9		10	12		7	15		5	17		11	11
Sokal risk groups
Low	64 (41.0)	44	20	0.085	28	36	0.746	30	34	0.870	27	37	0.870	21	43	0.098
Intermediate	52 (33.3)	45	7		27	25		30	22		20	32		24	28
High	40 (25.7)	30	10		16	24		11	29		17	23		19	21
Hasford risk groups
Low	55 (35.2)	42	13	1.00	25	30	0.240	22	33	0.318	25	30	0.496	19	36	0.724
Intermediate	65 (41.7)	53	12		35	30		33	32		21	44		22	43
High	36 (23.1)	24	12		22	14		16	20		18	18		10	26

CP: chronic phase, AP: accelerated phase, BP: blast phase, and variant*: heterozygous and homozygous variant genotypes.